PDCD1 and neoplasm: Although OX40 receptor engagement has been demonstrated to suppress the differentiation and activity of Tregs, there are also researches suggesting that the action of tumor vaccines was usually companied by a subsequent upregulation of Tregs and PD-1 expressing CD8+ T cells in tumor microenvironment [47–50].